Faecal Microbiota Transplantation for Liver Cirrhosis

Recruiting now · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Liver Cirrhosis

In brief

The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis. Further, the investigators want to examine the impact of FMT on the gut microbiota, gut barrier function, systemic inflammation, and immune function.

Key facts

Study ID

NCT04932577

Run by

University of Aarhus

People needed

220

Starts

2021-07-01

Expected to finish

2027-05-31

Last updated by the study team

2025-01-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 years
• Liver cirrhosis with Child-Pugh ≤ 12
• Acute decompensation requiring intervention (ascites, gastrointestinal bleeding, infections leading to progressive liver failure, overthepatic encephalopathy, alcoholic hepatitis)

You may not qualify if…

• More than one organ failure defined by CLIF-SOFA score
• Untreated malignancy apart from non-melanoma skin cancer
• Untreated viral hepatitis
• HIV
• Inflammatory bowel disease
• Celiac disease
• Clostridioides Difficile infection
• Pregnancy
• Unable to participate based on medical judgement

Where it is running

• Department of Hepatology and Gastroenterology, Aarhus University Hospital — Aarhus, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.